Want to see WVE full AI Analyst Report?
Top Page
Wave Life Sciences
(NASDAQ:WVE)
Select Model
Select Model
Rating:47Neutral
Price Target:
$3.50
▼(-33.33% Downside)
Action:Reiterated
Date:09/26/26
The score is held down primarily by weak financial performance (large, persistent losses and heavy cash burn) and bearish technicals (price below major moving averages with negative MACD). The main offset is the earnings call’s strong operational momentum and solid cash runway into Q3 2028, but valuation remains challenged due to ongoing losses and no dividend support.
Positive Factors
Clinical pipeline momentum
Wave is advancing multiple RNA-based candidates across obesity, alpha-1 antitrypsin deficiency, and liver disease. Progress into mid-stage development, completed dosing cohorts, and planned clinical submissions broaden potential future product opportunities and support platform validation.
Negative Factors
Persistent losses and cash burn
Wave remains structurally unprofitable, with operating losses translating into substantial cash outflows. Continued investment in clinical development may sustain this burden for several quarters, increasing dependence on existing reserves, collaboration receipts, milestone payments, or future financing.
Read all positive and negative factors
Positive Factors
Negative Factors
Clinical pipeline momentum
Wave is advancing multiple RNA-based candidates across obesity, alpha-1 antitrypsin deficiency, and liver disease. Progress into mid-stage development, completed dosing cohorts, and planned clinical submissions broaden potential future product opportunities and support platform validation.
Read all positive factors
Wave Life Sciences (WVE) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$674.52M
Dividend YieldN/A
Average Volume (3M)3.16M
Price to Earnings (P/E)―
Beta (1Y)1.97
Revenue Growth-30.42%
EPS Growth-23.31%
CountryUS
Employees317
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.09
Shares Outstanding197,228,060
10 Day Avg. Volume2,875,192
30 Day Avg. Volume3,155,473
Financial Highlights & Ratios
PEG Ratio-0.19
Price to Book (P/B)5.45
Price to Sales (P/S)67.10
P/FCF Ratio-15.29
Enterprise Value/Market Cap1.09
Enterprise Value/Revenue11.29
Enterprise Value/Gross Profit11.70
Enterprise Value/Ebitda-3.74
Forecast
1Y Price Target
$18.74Price Target Upside256.97% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering16
EPS Forecast (FY)-1.13
Revenue Forecast (FY)$50.44M
Wave Life Sciences Business Overview & Revenue Model
Company Description
Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company’s medicines platform, PRISM combines mult...
How the Company Makes Money
Wave Life Sciences generates revenue primarily through collaborations and licensing arrangements with larger pharmaceutical/biotechnology partners, which can include upfront payments, research funding or reimbursement, milestone payments tied to d...
Wave Life Sciences Earnings Call Summary
Earnings Call Date:Jul 30, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Oct 27, 2026
Earnings Call Sentiment Positive
The call emphasized substantial clinical momentum across the lead programs (WVE-007, WVE-006, WVE-008) with compelling early human and preclinical data, regulatory engagement (FDA meeting for 006), and a solid cash balance supporting operations into Q3 2028. Offsetting these positives are a pronounced YoY revenue decline (-73.6%), rising R&D and G&A spend driving a larger net loss (+37.4% YoY), dependency on future milestone payments not included in runway calculations, and timing/regulatory uncertainties (including partnership-driven strategy for DMD). On balance, the clinical and platform progress and runway position are dominant positives despite near-term financial headwinds and program/timing uncertainties.Positive Updates
Strong clinical readouts for WVE-007 (obesity)
Phase I single-dose INLIGHT data showed up to 88% serum Activin E reductions sustained through at least 7.5 months, preservation of lean mass, substantial reductions in visceral and subcutaneous fat after a single dose, and a 16.5% improvement in visceral fat-to-muscle ratio (VMR). FDA accepted the Phase IIa amendment and multi-dose dosing is underway (240 mg and 400 mg cohorts; two doses at Day 1 and Day 85; 4 cohorts of 40 patients each). Company pursuing combination (with incretins) and post-incretin maintenance studies this year.
Negative Updates
Significant decline in collaboration revenue
Q2 2026 revenue was $2.3 million versus $8.7 million in Q2 2025, a decline of approximately 73.6% year-over-year, driven by lower collaboration revenue from GSK.
Read all updates
Q2-2026 Updates
Positive
Negative
Strong clinical readouts for WVE-007 (obesity)
Phase I single-dose INLIGHT data showed up to 88% serum Activin E reductions sustained through at least 7.5 months, preservation of lean mass, substantial reductions in visceral and subcutaneous fat after a single dose, and a 16.5% improvement in visceral fat-to-muscle ratio (VMR). FDA accepted the Phase IIa amendment and multi-dose dosing is underway (240 mg and 400 mg cohorts; two doses at Day 1 and Day 85; 4 cohorts of 40 patients each). Company pursuing combination (with incretins) and post-incretin maintenance studies this year.
Read all positive updates
Company Guidance
On the call management reiterated operational and regulatory milestones and financial visibility: Q2 2026 results included revenue $2.3M (vs. $8.7M prior year), R&D $51.3M (vs. $43.5M), G&A $24.8M (vs. $18.0M), net loss $69.4M (vs. $50.5M), and $490.6M cash, cash equivalents and marketable securities (runway into Q3 2028, excluding expected GSK milestone payments in H2 2026). Clinical guidance: WVE‑007 (INLIGHT) moved into Phase IIa enrolling BMI 35–50 patients with and without T2D across two dose levels (240 mg and 400 mg) in 4 cohorts of 40 patients each (160 total), two doses (day 1 and day 85), 12‑month follow‑up with first key assessments at day 85, and plans to initiate combination and post‑GLP‑1 maintenance studies this year; Phase I single‑dose data showed Activin E reductions up to 88% sustained ≥7.5 months, VMR improvement 16.5% (vs. 12.2% semaglutide, 18.8% bimagrumab) and a 3.3% waist circumference reduction, and additional 600 mg data expected H2 2026. RNA editing guidance: WVE‑006 completed 200 mg biweekly, 400 mg monthly and 600 mg cohorts in RestorAATion‑2 with a planned FDA meeting end of summer to discuss accelerated approval for ~200,000 U.S./EU PiZZ AATD patients, and WVE‑008 (PNPLA3) is on track for a 2026 CTA with a therapeutic editing target benchmark of ~50% (addressing ~9M homozygous I148M carriers in U.S./Europe).Wave Life Sciences Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
56
Neutral
Cash Flow
20
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 65.37M | 42.73M | 108.30M | 113.31M | 3.65M | 40.96M |
| Gross Profit | 63.11M | 33.88M | 108.30M | 113.31M | 3.65M | 40.96M |
| EBITDA | -197.48M | -195.53M | -88.34M | -48.98M | -151.03M | -112.61M |
| Net Income | -202.47M | -204.38M | -97.01M | -57.51M | -161.82M | -122.25M |
Balance Sheet | ||||||
| Total Assets | 558.32M | 638.50M | 352.21M | 274.95M | 146.39M | 207.01M |
| Cash, Cash Equivalents and Short-Term Investments | 490.60M | 602.07M | 302.08M | 200.35M | 88.50M | 150.56M |
| Total Debt | 43.59M | 17.77M | 25.40M | 32.12M | 37.61M | 29.92M |
| Total Liabilities | 104.80M | 112.27M | 142.69M | 235.32M | 191.48M | 174.51M |
| Stockholders Equity | 453.52M | 526.23M | 209.51M | 39.63M | -45.09M | 32.50M |
Cash Flow | ||||||
| Free Cash Flow | -186.24M | -187.49M | -151.96M | -20.55M | -129.14M | -89.55M |
| Operating Cash Flow | -184.68M | -187.49M | -151.03M | -19.43M | -127.78M | -88.99M |
| Investing Cash Flow | -124.13M | -718.00K | -938.00K | -1.11M | -1.25M | -560.00K |
| Financing Cash Flow | 475.65M | 488.24M | 253.89M | 132.53M | 67.19M | 55.83M |
Wave Life Sciences Technical Analysis
Negative
5.25
Price Trends
4.32
Negative
5.11
Negative
7.81
Negative
Market Momentum
-0.32
Negative
37.06
Neutral
56.62
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For WVE, the sentiment is Negative. The current price of 5.25 is above the 20-day moving average (MA) of 3.50, above the 50-day MA of 4.32, and below the 200-day MA of 7.81, indicating a bearish trend. The MACD of -0.32 indicates Negative momentum. The RSI at 37.06 is Neutral, neither overbought nor oversold. The STOCH value of 56.62 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for WVE.
Wave Life Sciences Risk Analysis
Wave Life Sciences disclosed 72 risk factors in its most recent earnings report. Wave Life Sciences reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Wave Life Sciences Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | $857.80M | 5.29 | 90.98% | ― | 1078.78% | ― | |
55 Neutral | $312.09M | -3.32 | -46.54% | 1.29% | -82.95% | -49.04% | |
55 Neutral | $1.22B | -5.16 | -106.94% | ― | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $674.52M | -3.09 | -50.12% | ― | -30.42% | -23.31% | |
47 Neutral | $385.49M | -3.36 | -196.63% | ― | 20.83% | 73.89% | |
46 Neutral | $315.34M | -8.67 | -28.41% | 0.12% | ― | 14.04% |
* Healthcare Sector Average
WVE
Wave Life Sciences
3.37
-3.68
-52.20%
ABUS
Arbutus Biopharma
4.18
-0.10
-2.34%
ARCT
Arcturus Therapeutics
11.07
-0.93
-7.75%
BNTC
Benitec Biopharma
8.50
-7.31
-46.24%
EDIT
Editas Medicine
2.51
-1.14
-31.23%
SLN
Silence Therapeutics
19.67
12.42
171.31%
Wave Life Sciences Corporate Events
Business Operations and StrategyFinancial Disclosures
Wave Life Sciences posts Q2 results, pipeline update
Positive
Jul 30, 2026
Wave Life Sciences reported second-quarter 2026 results on July 30, 2026, alongside a business update highlighting progress across its RNA-based pipeline and an updated corporate presentation for investors. The company ended the quarter with $490....
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.